Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Mar;9(3):414-8.
doi: 10.1097/JTO.0000000000000065.

Systemic therapy, clinical outcomes, and overall survival in locally advanced or metastatic pulmonary carcinoid: a brief report

Patrick M Forde  1 , Craig M Hooker, Sosipatros A Boikos, Iacope Petrini, Giuseppe Giaccone, Charles M Rudin, Stephen C Yang, Peter B Illei, Christine L Hann, David S Ettinger, Julie R Brahmer, Ronan J Kelly
Affiliations

Systemic therapy, clinical outcomes, and overall survival in locally advanced or metastatic pulmonary carcinoid: a brief report

Patrick M Forde et al. J Thorac Oncol. 2014 Mar.

Abstract

Background: Data to guide the management of advanced pulmonary carcinoid (APC) come from retrospective reports and subgroup analyses of trials that included mainly extrapulmonary carcinoid tumors. We report the largest series to date of 49 patients with locally advanced or metastatic pulmonary carcinoid.

Methods: The Johns Hopkins Pathology Database was reviewed for APC patients treated between January 1992 and December 2012. Data on time to recurrence, progression-free survival, and overall survival were estimated by using the Kaplan-Meier method.

Results: Forty-nine patients were treated for APC in the specified time period. Median time to recurrence after surgical resection was 2.5 years (atypical carcinoid [AC] versus typical carcinoid [TC], 2.5 versus 6.3 years; p = 0.063). Median survival with advanced disease was 7.1 years and significantly longer for TC compared with AC (10.2 versus 4 years; p = 0.009). Among the diverse systemic therapies used, responses occurred in four of 17 patients (23.5%) who received platinum/etoposide with a median progression-free survival of 7 months.

Conclusion: Although systemic chemotherapy has moderate activity for APC, novel approaches are required. TC and AC, although both classified as pulmonary carcinoid, are clearly different clinical and molecular entities and require separate treatment paradigms in the advanced/metastatic setting.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Kaplan–Meier Curves of (A) time to recurrence after surgical resection and (B) overall survival from diagnosis of locally advanced or metastatic pulmonary carcinoid by histologic subtype.
See this image and copyright information in PMC

References

    1. Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC, editors. Pathology & Genetics: Tumours of the Lung, Pleura, Thymus and Heart. World Health Organization Classification of Tumours. Lyon, France: IARC Press; 2004. The concept of pulmonary neuroendocrine tumours; pp. 19–20.
    1. Travis WD, Rush W, Flieder DB, et al. Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. Am J Surg Pathol. 1998;22:934–944. - PubMed
    1. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003;97:934–959. - PubMed
    1. Hauso O, Gustafsson BI, Kidd M, et al. Neuroendocrine tumor epidemiology: contrasting Norway and North America. Cancer. 2008;113:2655–2664. - PubMed
    1. Fink G, Krelbaum T, Yellin A, et al. Pulmonary carcinoid: presentation, diagnosis, and outcome in 142 cases in Israel and review of 640 cases from the literature. Chest. 2001;119:1647–1651. - PubMed

MeSH terms